CLINICAL TRIALS PROFILE FOR POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

All Clinical Trials for Potassium Chloride 10meq In Dextrose 5% And Lactated Ringer's In Plastic Container

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00113685 ↗	Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury	Completed	National Heart, Lung, and Blood Institute (NHLBI)	N/A	2003-04-01	The purpose of this study is to evaluate the clinical outcome of patients following blunt traumatic injury with hypovolemic shock, who receive either lactated ringer's solution or hypertonic saline with dextran (HSD) resuscitation; also, to focus specifically on neurologic outcome in patients with brain injury and on the effect of HSD resuscitation on inflammatory cell responsiveness.
NCT00113685 ↗	Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury	Completed	University of Washington	N/A	2003-04-01	The purpose of this study is to evaluate the clinical outcome of patients following blunt traumatic injury with hypovolemic shock, who receive either lactated ringer's solution or hypertonic saline with dextran (HSD) resuscitation; also, to focus specifically on neurologic outcome in patients with brain injury and on the effect of HSD resuscitation on inflammatory cell responsiveness.
NCT00181077 ↗	Hypertonic Saline Use in Preeclampsia	Completed	Johns Hopkins University	Phase 1	2003-06-01	To compare hypertonic saline to Lactated Ringer's solution and assess whether one speeds up the process of getting rid of extra body water faster in women with preeclampsia.
NCT00311519 ↗	A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects	Completed	Halozyme Therapeutics	Phase 4	2005-11-01	The purpose of this research study to test the effectiveness of a study medication to increase how fast a solution called lactated Ringer's is absorbed when put under the skin subcutaneously. The medication to be studied is an enzyme called hyaluronidase, and is a human recombinant form of the enzyme. The drug company name for this medication is Hylenex. Hylenex was currently an investigational medication at the initiation of the study, but received FDA approval during the study. An investigational medication is a medication or formulation of a medication that is not approved by the United States Food and Drug Administration for use in this country but may be used in studies such as this one.
NCT00334360 ↗	Dexmed/Buspirone Synergism on Shivering	Completed	The Cleveland Clinic	Phase 4	2004-09-01	The purpose of this research is to determine if the combination of buspirone and dexmedetomidine are effective as a treatment to induce therapeutic hypothermia. The design of the study includes four study days done in random order. The days are as follows: 1) Control (no drug); 2) Buspirone 60 mg orally; 3) Dexmedetomidine (delivered by a computer-controlled IV infusion to a target plasma concentration of 0.6 ng/ml); and, 3) the combination of buspirone 60 mg and dexmedetomidine (target plasma concentration of 0.6 ng/ml). a 20 cm-long catheter will be inserted into a cubital vein using standard aseptic technique In addition to the PIC line catheter, a simple peripheral catheter will be inserted into the other arm for drug administration. Throughout the study period, mean-skin temperature will be maintained at 31°C by adjusting the temperature of circulating water (Cincinnati Sub-Zero, Cincinnati, OH) and forced-air warmers (Augustine Medical, Inc., Eden Prairie, MN). Furthermore, the back, upper-body, and lower-body will individually be maintained at the designated skin temperature. Lactated Ringer's solution cooled to ≈3°C will be infused via the PIC-line at rates sufficient to decrease tympanic membrane temperature ≈1.5°C/h. Fluid will be administered as long as oxygen consumption or electromyographic intensity (see below) continues to increase or a total of 5 liters of fluid is given. Heart rate will be measured continuously using an electrocardiogram; blood pressure will be determined oscillometrically at 5 min intervals at the ankle. In case heart rate and/or blood pressure changes unexpectedly (by more than 30% of the baseline), the study will stop and the volunteer will be re-warmed immediately.
NCT00395369 ↗	Effect of Intraoperative Aprotinin Administration on Post Cardiac Surgery Optic Nerve and Retinal Thickness.	Unknown status	Soroka University Medical Center	N/A	2007-12-01	Cognitive and neurological dysfunction after coronary artery bypass surgery (CABG) is common and multi-factorial in origin. Several previous studies have shown that intraoperative aprotinin administration may be neuroprotective.in the current prospective randomized study, the effect of intraoperative aprotinin administration on the integrity of the optic nerve and retinal nerve fiber layer will be examined. Optical coherance tomography will be used to examin the optic nerve and retinal nerve fiber layer.

Clinical Trial Conditions for Potassium Chloride 10meq In Dextrose 5% And Lactated Ringer's In Plastic Container

Condition Name

Condition Name for Potassium Chloride 10meq In Dextrose 5% And Lactated Ringer's In Plastic Container
Intervention	Trials
Anesthesia	5
Cesarean Section	4
Hypotension	4
Post-ERCP Acute Pancreatitis	4

Condition MeSH

Condition MeSH for Potassium Chloride 10meq In Dextrose 5% And Lactated Ringer's In Plastic Container
Intervention	Trials
Hypotension	16
Pancreatitis	11
Hemorrhage	10
Pain, Postoperative	8

Clinical Trial Locations for Potassium Chloride 10meq In Dextrose 5% And Lactated Ringer's In Plastic Container

Trials by Country

Trials by Country for Potassium Chloride 10meq In Dextrose 5% And Lactated Ringer's In Plastic Container
Location	Trials
Egypt	37
United States	33
China	12
Korea, Republic of	5
Brazil	4

Trials by US State

Trials by US State for Potassium Chloride 10meq In Dextrose 5% And Lactated Ringer's In Plastic Container
Location	Trials
Illinois	4
Connecticut	3
California	3
Pennsylvania	3
Minnesota	2

Clinical Trial Progress for Potassium Chloride 10meq In Dextrose 5% And Lactated Ringer's In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Potassium Chloride 10meq In Dextrose 5% And Lactated Ringer's In Plastic Container
Clinical Trial Phase	Trials
Phase 4	39
Phase 3	14
Phase 2/Phase 3	4

Clinical Trial Status

Clinical Trial Status for Potassium Chloride 10meq In Dextrose 5% And Lactated Ringer's In Plastic Container
Clinical Trial Phase	Trials
Completed	64
Not yet recruiting	29
Recruiting	26

Clinical Trial Sponsors for Potassium Chloride 10meq In Dextrose 5% And Lactated Ringer's In Plastic Container

Sponsor Name

Sponsor Name for Potassium Chloride 10meq In Dextrose 5% And Lactated Ringer's In Plastic Container
Sponsor	Trials
Ain Shams University	9
Cairo University	6
Mansoura University	5

Sponsor Type

Sponsor Type for Potassium Chloride 10meq In Dextrose 5% And Lactated Ringer's In Plastic Container
Sponsor	Trials
Other	214
Industry	17
NIH	2

Potassium Chloride 10 mEq in Dextrose 5% and Lactated Ringer's: Clinical Trials, Market Analysis, and Projections

Overview of Potassium Chloride in Dextrose 5% and Lactated Ringer's

Potassium Chloride in Dextrose 5% and Lactated Ringer's is a parenteral solution used to treat hypokalemia, replace extracellular losses of fluids and electrolytes, and provide minimal carbohydrate calories. This solution is crucial in clinical settings for maintaining electrolyte balance and fluid status in patients.

Clinical Trials

Current Status and Trends

Clinical trials involving Potassium Chloride in Dextrose 5% and Lactated Ringer's are primarily focused on its efficacy and safety in various patient populations. Here are some key points:

• Phase 3 and 4 Trials: Many Phase 3 and 4 trials have been conducted to evaluate the long-term safety and efficacy of this solution. These trials often compare different dosing regimens and patient outcomes, such as the prevention of hypokalemia and the management of fluid balance[5].

• Pediatric and Geriatric Populations: There is a growing interest in trials that focus on pediatric and geriatric patients. These studies aim to determine the optimal dosing and administration protocols for these vulnerable populations, given their unique physiological needs and potential for adverse reactions[4].

• Combination Therapies: Some trials explore the use of Potassium Chloride in Dextrose 5% and Lactated Ringer's in combination with other medications, such as diuretics or ACE inhibitors, to manage complex clinical conditions like heart failure or severe metabolic disturbances[2].

Ongoing and Future Trials

Several ongoing and planned clinical trials are investigating new indications and uses for this solution:

• Critical Care Settings: Trials are being conducted to evaluate the role of Potassium Chloride in Dextrose 5% and Lactated Ringer's in critical care settings, particularly in patients with severe trauma, burns, or those undergoing major surgery[4].

• Renal Impairment: Studies are focusing on patients with renal impairment to determine safe and effective dosing strategies, given the risk of hyperkalemia in this population[3].

Market Analysis

Market Size and Growth

The market for parenteral solutions, including Potassium Chloride in Dextrose 5% and Lactated Ringer's, is significant and growing due to increasing demand in hospitals and healthcare facilities.

• Global Market: The global market for intravenous solutions is projected to grow at a CAGR of around 5-7% over the next few years, driven by the increasing incidence of chronic diseases, the need for fluid and electrolyte replacement, and advancements in healthcare infrastructure[4].

• Regional Markets: The market is particularly strong in regions with well-developed healthcare systems, such as North America and Europe. However, emerging markets in Asia-Pacific and Latin America are also showing rapid growth due to improving healthcare access and increasing healthcare spending.

Competitive Landscape

The market for Potassium Chloride in Dextrose 5% and Lactated Ringer's is competitive, with several key players:

• Major Manufacturers: Companies like Pfizer, Baxter International, and B. Braun Medical are major players in this market. These companies invest heavily in research and development to improve product formulations and administration methods[1][4].

• Generic and Biosimilar Options: The availability of generic and biosimilar versions of these solutions has increased competition, making them more accessible and affordable for a broader range of patients.

Market Projections

Future Trends

Several trends are expected to shape the market for Potassium Chloride in Dextrose 5% and Lactated Ringer's in the coming years:

• Advancements in Formulation: There is a growing interest in developing more stable and convenient formulations, such as ready-to-use solutions and pre-mixed bags, which can reduce preparation time and minimize the risk of errors[4].

• Personalized Medicine: The trend towards personalized medicine is expected to influence the use of Potassium Chloride in Dextrose 5% and Lactated Ringer's, with more tailored dosing regimens based on individual patient needs and genetic profiles.

• Cost-Effectiveness: With increasing pressure to reduce healthcare costs, there will be a greater emphasis on cost-effective solutions. This could lead to a greater adoption of generic and biosimilar products.

Economic Impact

The economic impact of Potassium Chloride in Dextrose 5% and Lactated Ringer's is significant:

• Healthcare Savings: By preventing and treating hypokalemia effectively, this solution can help reduce the overall cost of healthcare by minimizing the need for prolonged hospital stays and reducing the incidence of complications[3].

• Market Value: The market value of Potassium Chloride in Dextrose 5% and Lactated Ringer's is expected to increase, driven by the growing demand for parenteral solutions and the expanding patient population requiring these treatments.

Key Takeaways

• Clinical Trials: Ongoing and future trials are focusing on the safety, efficacy, and optimal use of Potassium Chloride in Dextrose 5% and Lactated Ringer's in various patient populations.
• Market Growth: The market for this solution is growing, driven by increasing demand and advancements in healthcare.
• Competitive Landscape: The market is competitive, with major manufacturers and generic/biosimilar options available.
• Future Trends: Advancements in formulation, personalized medicine, and cost-effectiveness will shape the future of this market.

FAQs

What is the primary use of Potassium Chloride in Dextrose 5% and Lactated Ringer's?

The primary use is to treat hypokalemia, replace extracellular losses of fluids and electrolytes, and provide minimal carbohydrate calories.

What are the key components of Potassium Chloride in Dextrose 5% and Lactated Ringer's?

The solution contains potassium chloride, dextrose, sodium chloride, sodium lactate, and calcium chloride dihydrate[4].

What are the contraindications for using Potassium Chloride in Dextrose 5% and Lactated Ringer's?

It is contraindicated in diseases where high potassium levels may be encountered and in the treatment of lactic acidosis[4].

How should Potassium Chloride in Dextrose 5% and Lactated Ringer's be administered?

It should be administered only by intravenous infusion, with the dose and rate dependent on the patient's age, weight, and clinical condition[4].

What are the potential risks associated with Potassium Chloride in Dextrose 5% and Lactated Ringer's?

Potential risks include hyperkalemia, fluid overload, hyperglycemia, and metabolic alkalosis. Continuous monitoring of serum potassium levels and other electrolytes is essential[2][4].

Sources

1. Pfizer Medical Information: Potassium Chloride for Injection Concentrate, USP Dosage and Administration.
2. FDA Label: Potassium Chloride in Lactated Ringer's and 5% Dextrose Injection, USP.
3. Drugs.com: Potassium Chloride: Package Insert / Prescribing Information.
4. Drugs.com: Potassium Chloride in Lactated Ringers and Dextrose - Drugs.com.
5. DrugBank: Potassium chloride: Uses, Interactions, Mechanism of Action.